Melanoma is a rare malignant tumor in China;however,its mortality rate is high and the incidence rate is also increasing year by year.In order to improve the efficacy of melanoma treatment,the National Health Commissi...Melanoma is a rare malignant tumor in China;however,its mortality rate is high and the incidence rate is also increasing year by year.In order to improve the efficacy of melanoma treatment,the National Health Commission of the People’s Republic of China revised Chinese guidelines for diagnosis and treatment of melanoma in 2018,and meanwhile its modified English version Chinese guidelines for diagnosis and treatment of melanoma 2018(English version)(1)is also published.Based on the most updated research findings for the Chinese ethnicity with emphasis on acral and mucosal melanomas,two most commonly seen subtypes in Asia,as well as treatment for melanoma liver metastases.展开更多
Dear Editor,Extramammary Paget disease(EMPD)is a rare adenocarcinoma that originates in the apocrine gland-rich skin and usually affects the perineal skin(primary EMPD)or represents the intraepithelial spread of an un...Dear Editor,Extramammary Paget disease(EMPD)is a rare adenocarcinoma that originates in the apocrine gland-rich skin and usually affects the perineal skin(primary EMPD)or represents the intraepithelial spread of an underlying visceral carcinoma(secondary EMPD).Approximately half of EMPD cases are confined to the epidermis,which was defined as intraepithelial EMPD.展开更多
The BRAF gene is an important signaling molecule in human cells that is involved in the regulation of cell growth,differentiation,and survival.When the BRAF gene mutates,it can lead to abnormal activation of the signa...The BRAF gene is an important signaling molecule in human cells that is involved in the regulation of cell growth,differentiation,and survival.When the BRAF gene mutates,it can lead to abnormal activation of the signaling pathway,which promotes cell proliferation,inhibits cell apoptosis,and ultimately contributes to the occurrence and development of cancer.BRAF mutations are widely present in various cancers,including malignant melanoma,thyroid cancer,colorectal cancer,non-small cell lung cancer,and hairy cell leukemia,among others.BRAF is an important target for the treatment of various solid tumors,and targeted combination therapies,represented by BRAF inhibitors,have become one of the main treatment modalities for a variety of BRAF-mutation-positive solid tumors.展开更多
IBI310 is a recombinant fully human IgG1 antibody against cytotoxic T lymphocyte antigen 4.This study was conducted to evaluate IBI310 monotherapy or combination therapy with sintilimab in the patients with advanced m...IBI310 is a recombinant fully human IgG1 antibody against cytotoxic T lymphocyte antigen 4.This study was conducted to evaluate IBI310 monotherapy or combination therapy with sintilimab in the patients with advanced melanoma or urothelial carcinoma(UC).Patients in phase 1a received IBI310 at 0.3/1/2/3 mg/kg intravenously(IV)every 3 weeks(Q3W)following the accelerated titration and 3+3 escalation design.Patients in phase 1b received IBI310(1/2/3 mg/kg IV,Q3W)plus sintilimab(200 mg IV,Q3W)for four cycles,followed by sintilimab maintenance therapy.The phase 1b expansion of IBI310 plus sintilimab was performed in patients with advanced melanoma or UC.Overall,53 patients were enrolled,including 10 patients with melanoma in phase 1a,34 with melanoma,and 9 with UC in phase 1b.Overall,94.3%of patients(50/53)experienced at least one treatment-related adverse event(TRAE)with most being grade 1–2;26.4%of patients(14/53)experienced grade 3 or higher TRAEs.In phase 1a,the disease control rate(DCR)was 50.0%(95%confidence interval[CI],18.7%–81.3%).In phase 1b,the objective response rate(ORR)and DCR were 17.6%(95%CI,6.8%–34.5%)and 44.1%(95%CI,27.2%–62.1%),respectively,for melanoma,and were 22.2%(95%CI,2.8%–60.0%)and 66.7%(95%CI,29.9%–92.5%),respectively,for UC.IBI310 monotherapy or combination therapy with sintilimab was well tolerated with favorable antitumor activity across patients with advanced melanoma and UC.展开更多
A new in-line Mach-Zehnder interferometer （MZI） sensor consisting of a stub of multi-mode fiber and an up-taper was proposed and demonstrated. Temperature measurement can be carried out by detecting wavelength shift...A new in-line Mach-Zehnder interferometer （MZI） sensor consisting of a stub of multi-mode fiber and an up-taper was proposed and demonstrated. Temperature measurement can be carried out by detecting wavelength shift. Dependency of sensitivity on interferometer length and dip wavelength was discussed. Experimental results showed a maximum temperature sensitivity of 113.6pm/℃ can be achieved, which is superior to most fiber temperature sensors based on in-line MZIs within the range from 20℃ to 80℃, also a good mechanical strength can be obtained. The proposed sensor is a good candidate for temperature measurement, due to the advantages of simple structure, easy fabrication, cost- effective and high sensitivity.展开更多
文摘Melanoma is a rare malignant tumor in China;however,its mortality rate is high and the incidence rate is also increasing year by year.In order to improve the efficacy of melanoma treatment,the National Health Commission of the People’s Republic of China revised Chinese guidelines for diagnosis and treatment of melanoma in 2018,and meanwhile its modified English version Chinese guidelines for diagnosis and treatment of melanoma 2018(English version)(1)is also published.Based on the most updated research findings for the Chinese ethnicity with emphasis on acral and mucosal melanomas,two most commonly seen subtypes in Asia,as well as treatment for melanoma liver metastases.
基金supported by Beijing Medical Award Foundation(No.YXJL-2020-0889-0106)Beijing Municipal Administration of Hospitals’Ascent Plan(No.DFL20220901)Beijing Xisike Clinical Oncology Research Foundation(Nos.Y-Roche2019/2-0076 and Y-SY201901-0270).
文摘Dear Editor,Extramammary Paget disease(EMPD)is a rare adenocarcinoma that originates in the apocrine gland-rich skin and usually affects the perineal skin(primary EMPD)or represents the intraepithelial spread of an underlying visceral carcinoma(secondary EMPD).Approximately half of EMPD cases are confined to the epidermis,which was defined as intraepithelial EMPD.
基金supported by the Natural Science Foundation of China(grant number 82002456)China Postdoctoral Science Foundation(grant number 2022M723207)+10 种基金the Medical Scientific Research Foundation of Zhejiang Province,China(grant number 2023KY666)Zhejiang Traditional Chinese Medicine Science Fund Project(grant number 2024ZL372)Qiantang Cross Fund Project(grant number 2023-16)National Natural Science Foundation of China of Zhejiang Cancer Hospital Cultivation Project(grant number PY2023006)the Medical Scientific Research Foundation of Zhejiang Province,China(grant number 2024KY812)the Natural Science Foundation of Zhejiang Province(grant number LQ24H160036)Beijing Health Technologies Promotion Program[grant number BHTPP2022041]Peking University Clinical Scientist Training Program and the Fundamental Research Funds for the Central Universities[grant number BMU2024PYJH010]Science Foundation of Peking University Cancer Hospital[grant number PY202333]the Beijing Natural Science Foundation[grant number 7232248]Beijing Hospitals Authority Youth Programme[grant number QML20231902].
文摘The BRAF gene is an important signaling molecule in human cells that is involved in the regulation of cell growth,differentiation,and survival.When the BRAF gene mutates,it can lead to abnormal activation of the signaling pathway,which promotes cell proliferation,inhibits cell apoptosis,and ultimately contributes to the occurrence and development of cancer.BRAF mutations are widely present in various cancers,including malignant melanoma,thyroid cancer,colorectal cancer,non-small cell lung cancer,and hairy cell leukemia,among others.BRAF is an important target for the treatment of various solid tumors,and targeted combination therapies,represented by BRAF inhibitors,have become one of the main treatment modalities for a variety of BRAF-mutation-positive solid tumors.
基金supported by grants from Beijing Health Technologies Promotion Program(BHTPP2022041)Peking University Clinical Scientist Training Program,the Fundamental Research Funds for the Central Universities(BMU2024PYJH010)+2 种基金Beijing Municipal Administration of Hospitals Incubating Program(PX2021046)Science Foundation of Peking University Cancer Hospital(PY202333)Innovent Biologics,Inc.,Suzhou,China.The funder,Innovent Biologics,was involved in the study design,data collection,data analysis,and data interpretation.
文摘IBI310 is a recombinant fully human IgG1 antibody against cytotoxic T lymphocyte antigen 4.This study was conducted to evaluate IBI310 monotherapy or combination therapy with sintilimab in the patients with advanced melanoma or urothelial carcinoma(UC).Patients in phase 1a received IBI310 at 0.3/1/2/3 mg/kg intravenously(IV)every 3 weeks(Q3W)following the accelerated titration and 3+3 escalation design.Patients in phase 1b received IBI310(1/2/3 mg/kg IV,Q3W)plus sintilimab(200 mg IV,Q3W)for four cycles,followed by sintilimab maintenance therapy.The phase 1b expansion of IBI310 plus sintilimab was performed in patients with advanced melanoma or UC.Overall,53 patients were enrolled,including 10 patients with melanoma in phase 1a,34 with melanoma,and 9 with UC in phase 1b.Overall,94.3%of patients(50/53)experienced at least one treatment-related adverse event(TRAE)with most being grade 1–2;26.4%of patients(14/53)experienced grade 3 or higher TRAEs.In phase 1a,the disease control rate(DCR)was 50.0%(95%confidence interval[CI],18.7%–81.3%).In phase 1b,the objective response rate(ORR)and DCR were 17.6%(95%CI,6.8%–34.5%)and 44.1%(95%CI,27.2%–62.1%),respectively,for melanoma,and were 22.2%(95%CI,2.8%–60.0%)and 66.7%(95%CI,29.9%–92.5%),respectively,for UC.IBI310 monotherapy or combination therapy with sintilimab was well tolerated with favorable antitumor activity across patients with advanced melanoma and UC.
基金Acknowledgements This work was supported by the National Natural Science Foundation of China （Nos. 61275083 and 61290315） and the Fundamental Research Funds for the Central Universities （HUST： No. 2014CG002）.
文摘A new in-line Mach-Zehnder interferometer （MZI） sensor consisting of a stub of multi-mode fiber and an up-taper was proposed and demonstrated. Temperature measurement can be carried out by detecting wavelength shift. Dependency of sensitivity on interferometer length and dip wavelength was discussed. Experimental results showed a maximum temperature sensitivity of 113.6pm/℃ can be achieved, which is superior to most fiber temperature sensors based on in-line MZIs within the range from 20℃ to 80℃, also a good mechanical strength can be obtained. The proposed sensor is a good candidate for temperature measurement, due to the advantages of simple structure, easy fabrication, cost- effective and high sensitivity.
